Key Drivers
- Strong liquidity
- Persistent losses
- No revenue
AIAI Summary
ANRO should now be viewed less as a financing-risk story and more as a cash-backed, single-catalyst biotech where the investment case hinges on ALTO-207 Phase 2b translating prior signal into real efficacy, while the ALTO-101 miss keeps execution risk and program selectivity front and center.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Persistent losses
- •No revenue
ANRO has a very strong net-cash balance sheet, but persistent losses, negative cash flow, and no revenue mean the investment case still depends more on capital strength than operating performance.
Price Behavior
Key Price Behavior Insights:
- •Downtrend intact
- •Support being tested
- •Failed bounce
ANRO remains in a short-term downtrend after sliding from 27.72 to 22.98 and closing near the bottom of its last month range, with $22.85-$23.00 as key support and a reclaim of $24.63 needed to improve the setup.
Sharp drop from $24.63 on 2026-05-12 to $22.85 on 2026-05-13 signaled failed support
Sentiment & News
Key News Insights:
- •Phase 2b Start
- •Phase 2a Data
- •Pipeline Momentum
Alto Neuroscience reinforced its growth story by advancing ALTO-207 into Phase 2b, sharing supportive Phase 2a data, and highlighting steady pipeline and investor engagement.
The update is modestly positive for ANRO, underscoring clinical progress and keeping ALTO-207 in focus for investors
Similar Companies in Healthcare
Other companies in the same sector with AI ratings